This assignment focuses on the drug bardoxolone methyl and its use in treating chronic kidney disease (CKD), particularly in patients with type 2 diabetes. It examines various clinical trials, such as the BEACON trial, and analyzes their findings regarding the efficacy and safety of bardoxolone methyl in slowing the progression of CKD. The assignment also delves into the broader context of CKD, its association with cardiovascular risk, and the implications for patient management.